Patient characteristics of the transplantation cohort (n = 432)
| . | Value . |
|---|---|
| Median age, y (range) | 51 (0-74) |
| Age | |
| 0-17 y, n (%) | 35 (8) |
| 18-30 y, n (%) | 56 (13) |
| 31-40 y, n (%) | 49 (11) |
| 41-50 y, n (%) | 75 (17) |
| 51-60 y, n (%) | 126 (29) |
| 61-80 y, n (%) | 91 (21) |
| Sex | |
| Male, n (%) | 229 (53) |
| Female, n (%) | 203 (47) |
| Conditioning | |
| MA, n (%) | 295 (68) |
| NMA, n (%) | 137 (32) |
| Donor | |
| Allo related, n (%) | 154 (36) |
| Allo unrelated, n (%) | 272 (63) |
| Auto, n (%) | 6 (1) |
| Stem cell source | |
| BM, n (%) | 64 (15) |
| PBSC, n (%) | 319 (74) |
| Cord, n (%) | 49 (11) |
| Cytogenetic risk before treatment | |
| Good, n (%) | 30 (7) |
| Intermediate, n (%) | 254 (59) |
| Poor, not MK, n (%) | 88 (20) |
| Poor, MK, n (%) | 60 (14) |
| Status at transplantation | |
| Remission, n (%)* | 353 (82) |
| Relapse, n (%) | 79 (18) |
| . | Value . |
|---|---|
| Median age, y (range) | 51 (0-74) |
| Age | |
| 0-17 y, n (%) | 35 (8) |
| 18-30 y, n (%) | 56 (13) |
| 31-40 y, n (%) | 49 (11) |
| 41-50 y, n (%) | 75 (17) |
| 51-60 y, n (%) | 126 (29) |
| 61-80 y, n (%) | 91 (21) |
| Sex | |
| Male, n (%) | 229 (53) |
| Female, n (%) | 203 (47) |
| Conditioning | |
| MA, n (%) | 295 (68) |
| NMA, n (%) | 137 (32) |
| Donor | |
| Allo related, n (%) | 154 (36) |
| Allo unrelated, n (%) | 272 (63) |
| Auto, n (%) | 6 (1) |
| Stem cell source | |
| BM, n (%) | 64 (15) |
| PBSC, n (%) | 319 (74) |
| Cord, n (%) | 49 (11) |
| Cytogenetic risk before treatment | |
| Good, n (%) | 30 (7) |
| Intermediate, n (%) | 254 (59) |
| Poor, not MK, n (%) | 88 (20) |
| Poor, MK, n (%) | 60 (14) |
| Status at transplantation | |
| Remission, n (%)* | 353 (82) |
| Relapse, n (%) | 79 (18) |
MA indicates myeloablative; NMA, nonmyeloablative; and PBSC, peripheral blood stem cell.
The breakdown was 228 (65%) in first remission, 101 (29%) in second remission, 16 (4.5%) in greater than second remission, and 8 (2.3%) unknown.